Business
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for the treatment of chronic primary immune thrombocytopenia Business development: Acquired an economic interest in Castle Creek Biosciences’ D-Fi (FCX-007) through participation in a syndicated royalty financing transaction and successfully sold al
About this update from Xoma Royalty Corporation
[{"type":"image","alt":"XOMA Royalty Corporation","displaySize":"","headline":null,"caption":"XOMA Royalty Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":143,"url":"https://media.zenfs.com/en/globenewswire.com/19abcc56f18b6f846d93450ed04d16d8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9T1bwIBIjaqPMJV2m8ecng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/19abcc56f18b6f846d93450ed04d16d8","width":300,"height":143}},"lazy":false},{"type":"text","content":"Pipeline advancements: The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA) and Takeda initiated its Phase 3 trial exploring mezagitamab for the treatment of chronic primary immune thrombocytopenia","length":311,"tagName":"p"},{"type":"text","content":"Business development: Acquired an economic interest in Castle Creek Biosciences’ D-Fi (FCX-007) through participation in a syndicated royalty financing transaction and successfully sold all unpartnered Kinnate assets ","length":216,"tagName":"p"},{"type":"text","content":"Cash receipts: Received $18.0 million in the first quarter of 2025 including $13.4 million in royalty receipts ","length":110,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2025 financial results and highlighted recent actions that have the potential to deliver shareholder value.","length":261,"tagName":"p"},{"type":"text","content":"“We are committed to generating value for shareholders through prudent cash deployment, strict expense control, and opportunistic share repurchases. Our first quarter highlights included the progression of key pipeline assets, solid cash receipts, and an increase in our share repurchase activity,” stated Owen Hughes, Chief Executive Officer of XOMA Royalty. “With accelerating royalty receipts and a robust pipeline, we believe a path to sustained cashflow generation is tangible.”","length":489,"tagName":"p"},{"type":"text","content":"Royalty and Milestone Acquisitions","length":34,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:20%;width:20%;min-width:20%;...